Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1

Loading news article.

Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1 | WAPE

Article summary